Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Smolen, Josef S; Schoels, Monika M; Nishimoto, Norihiro; Breedveld, Ferdinand C; Burmester, Gerd R; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Gabay, Cem; Gibofsky, Allan; Gomez-Reino, Juan Jesus; Jones, Graeme; Kvien, Tore K; Murakami, Miho; Betteridge, Neil; Bingham, Clifton O (3rd); Bykerk, Vivian; Choy, Ernest H; Combe, Bernard; Cutolo, Maurizio; Graninger, Winfried; Lanas, Angel; Martin-Mola, Emilio; Montecucco, Carlomaurizio; Ostergaard, Mikkel; Pavelka, Karel; Rubbert-Roth, Andrea; Sattar, Naveed; Scholte-Voshaar, Marieke; Tanaka, Yoshiya; Trauner, Michael; Valentini, Gabriele; Winthrop, Kevin L; de Wit, Maarten; van der Heijde, Désirée

doi:10.1136/annrheumdis-2012-202469

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Authors		Smolen, Josef S Schoels, Monika M Nishimoto, Norihiro Breedveld, Ferdinand C Burmester, Gerd R Dougados, Maxime Emery, Paul Ferraccioli, Gianfranco Gabay, Cem Gibofsky, Allan Gomez-Reino, Juan Jesus Jones, Graeme Kvien, Tore K Murakami, Miho Betteridge, Neil Bingham, Clifton O (3rd) Bykerk, Vivian Choy, Ernest H Combe, Bernard Cutolo, Maurizio Graninger, Winfried Lanas, Angel Martin-Mola, Emilio Montecucco, Carlomaurizio Ostergaard, Mikkel Pavelka, Karel Rubbert-Roth, Andrea Sattar, Naveed Scholte-Voshaar, Marieke Tanaka, Yoshiya Trauner, Michael Valentini, Gabriele Winthrop, Kevin L de Wit, Maarten van der Heijde, Désirée show all authors [1 - 35]
Published in		Annals of the Rheumatic Diseases. 2013, vol. 72, no. 4, p. 482-92
Abstract		Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.
Keywords		Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects — Antirheumatic Agents/administration & dosage/adverse effects — Arthritis, Rheumatoid/drug therapy/immunology — Drug Monitoring/methods — Humans — Inflammation/drug therapy/immunology — Interleukin-6/antagonists & inhibitors — Receptors, Interleukin-6/antagonists & inhibitors
Identifiers		DOI: 10.1136/annrheumdis-2012-202469 PMID: 23172750
Full text		Article (Published version) (238 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Mécanisme de l'inflammation articulaire (44)
Citation (ISO format)		SMOLEN, Josef S et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. In: Annals of the Rheumatic Diseases, 2013, vol. 72, n° 4, p. 482-92. https://archive-ouverte.unige.ch/unige:45809